REG - Oxford Biomedica PLC - Holding(s) in Company <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

26/02/2016 16:50

RNS Number : 3679Q
Oxford Biomedica PLC
26 February 2016
For filings with the FCA include the annex

For filings with issuer exclude the annex


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Oxford Biomedica plc 
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights 

Other (please specify):
CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING
3. Full name of person(s) subject to the
notification obligation:iii
Aviva plc & its subsidiaries 
4. Full name of shareholder(s)
(if different from 3.):iv
Registered Holder:
BNY Norwich Union Nominees Limited 15,256,044*
Chase (GA Group) Nominees Limited 205,609,901*

State Street Nominees Limited  2,159,221*
*denotes direct interest 
Chase (GA Group) Nominees Limited 20,807,732
Chase Nominees Limited 7,493,906
Vidacos Nominees Limited 11,939,558
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
25 February 2016
6. Date on which issuer notified:
26 February 2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
11% to 10% at Combined Interest Level 
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
Ordinary Shares 

GB00066458157
283,550,521*
283,550,521*
263,266,362
223,025,166
40,241,196
8.25%
1.49%

* Includes Right to Recall Loaned Shares (21,365,559)
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
RIGHT TO RECALL LOANED SHARES
N/A
N/A
20,284,159*
*DIRECT INTEREST
0.75%
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta


Total (A+B+C)
Number of voting rights
Percentage of voting rights
283,550,521
10.49%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited:
 Aviva plc (Parent Company)
 Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)
 Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)
 Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Proxy Voting:
10. Name of the proxy holder:
See Section 4
11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:



13. Additional information:

Figures are based the total number of voting rights of 2,702,853,244 as per the Company's Placing Announcement of 23 February 2016.
14. Contact name:
Tim Watts
Chief Financial Officer, Oxford BioMedica
15. Contact telephone number:
+44 (0) 1865 783 000

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUNONRNWAUUAR